NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Pharmacokinetic Study of Tenofovir Alafenamide (TAF)/Elvitegravir (EVG) Administered Rectally

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: TAF/EVG Insert

First Posted Date: 2019-08-06

Last Posted Date: 2023-12-22

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 23

Registration Number: NCT04047420

Locations: 🇺🇸
University of Pittsburgh CRS, Pittsburgh, Pennsylvania, United States
🇺🇸
Alabama CRS, Birmingham, Alabama, United States

H1N1v Virus Challenge Study in Healthy Subjects

Phase 1

Completed

Conditions: Influenza

Interventions: Biological: Influenza A/Bethesda/MM2/H1N1 Challenge

First Posted Date: 2019-08-05

Last Posted Date: 2021-04-28

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 76

Registration Number: NCT04044352

Locations: 🇺🇸
Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati, Ohio, United States
🇺🇸
Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States
🇺🇸
University of Maryland Baltimore - School of Medicine - Medicine, Baltimore, Maryland, United States

and more 1 locations

Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy Adults

Phase 1

Completed

Conditions: Ebola Virus

Interventions: Biological: cAd3-EBO S vaccine

First Posted Date: 2019-08-01

Last Posted Date: 2022-12-06

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 40

Registration Number: NCT04041570

Locations: 🇺🇬
Makerere University-Walter Reed Project, Kampala, Uganda

Evaluating the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of GEO-D02 DNA and MVA/HIV62B With and Without B63521^11 gp120 and IHV01 gp120 Env Proteins in Healthy, HIV-uninfected Adult Participants

Phase 1

Withdrawn

Conditions: HIV Infections

Interventions: Biological: GEO-D02 DNA
Biological: MVA/HIV62B Vaccine
Biological: IHV01 Protein
Biological: B63521^11 gp120
Biological: Protein Placebo

First Posted Date: 2019-08-01

Last Posted Date: 2021-10-15

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT04041674

Febrile Disease Landscape in Cambodia Via Metagenomic Pathogen Sequencing

Recruiting

Conditions: Emerging Pathogens
Vector-Borne Diseases

First Posted Date: 2019-07-26

Last Posted Date: 2024-12-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 6500

Registration Number: NCT04034264

Locations: 🇰🇭
Preah Kossomak Hospital, Phnom Penh, Cambodia
🇰🇭
Takeo District Referral Hospital, Takeo, Cambodia
🇰🇭
National Pediatric Hospital, Phnom Penh, Cambodia

and more 1 locations

Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine

Phase 2

Completed

Conditions: Healthy Volunteer

Interventions: Biological: Flucelvax
Biological: Fluvirin
Biological: Fluzone High Dose

First Posted Date: 2019-07-19

Last Posted Date: 2024-01-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 98

Registration Number: NCT04025580

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Glutamine Supplementation in People With Immune Dysregulation

Early Phase 1

Withdrawn

Conditions: Eczema
MTOROC1 Signaling

Interventions: Drug: L-glutamine

First Posted Date: 2019-07-15

Last Posted Date: 2020-03-16

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT04019769

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects

Phase 1

Completed

Conditions: Rabies Immunisation
Rabies

Interventions: Biological: ChAd155-RG
Other: Placebo
Biological: Rabies Vaccine

First Posted Date: 2019-07-15

Last Posted Date: 2024-06-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 50

Registration Number: NCT04019444

Locations: 🇺🇸
The Hope Clinic of Emory University, Decatur, Georgia, United States

Evaluating the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine

Phase 1

Completed

Conditions: Mosquito-Borne Infectious Diseases

Interventions: Biological: AGS-v PLUS Vaccine
Biological: Montanide ISA-51 Adjuvant
Biological: Alhydrogel® Adjuvant
Biological: Saline Placebo

First Posted Date: 2019-07-05

Last Posted Date: 2022-04-28

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 51

Registration Number: NCT04009824

Locations: 🇺🇸
University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States

Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Malaria Transmission Season in Healthy African Adult Women of Childbearing Potential in Mali

Phase 2

Completed

Conditions: Malaria

Interventions: Biological: PfSPZ Vaccine
Other: Normal Saline

First Posted Date: 2019-06-18

Last Posted Date: 2024-03-19

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 324

Registration Number: NCT03989102

Locations: 🇲🇱
Ouelessebougou Health Research Unit, Ouelessebougou, Mali

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy